Bydureon vs Ozempic

Drug comparison

Last updated 2026-05-28 15:46 UTC

Bydureon (exenatide by AstraZeneca) and Ozempic (semaglutide by Novo Nordisk) are both injectable medications for type 2 diabetes, given under the skin. Ozempic is also approved to lower cardiovascular risk and help with chronic kidney disease, while Bydureon is only approved for diabetes.

AI summary of the sources below.

	Bydureon	Ozempic
Active ingredient	exenatide	semaglutide
Manufacturer	astrazeneca	novo-nordisk
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	type 2 diabetes, cardiovascular risk reduction, chronic kidney disease
Label updated	—	2026-01-30

Compare full details on the Bydureon and Ozempic pages.